Therapeutic Cancer Vaccines for Nonmelanoma Skin Cancer
Authors:
- 28 March 2023
- journal article
- review article
- Published by Springer Nature in Current Treatment Options in Oncology
- Vol. 24 (5) , 496-514
Abstract
Opinion statement The development of immunotherapies for nonmelanoma skin cancer (NMSC) has lagged far behind that for melanoma in the past few decades, given that the majority of cases are surgically curable. Nevertheless, given the steady growth in the incidence rate of NMSC and attendant increase in patients with unresectable or advanced-stage tumors, the demand for systemic therapy is noticeably increasing. To date, the most widely used immunotherapeutic strategies, including immune checkpoint inhibitors and T-cell therapy, have obtained satisfactory results in some patients but not others. Even with an objective response in a fraction of patients, some accompanying adverse events may lead to intolerance and noncompliance. The expanding understanding of immune surveillance and tumor escape has provided us with novel perspectives in the field of immunotherapy. One emerging approach, the therapeutic cancer vaccine, encompasses the potential to newly “prime” T cells by activating antigen presentation in regional lymph nodes and the tumor microenvironment. Immune cells are therefore preconditioned and awakened to be ready to attack tumors. In NMSCs, multiple clinical trials of cancer vaccines are underway. The vaccine targets include tumor-associated antigens, tumor-specific antigens, oncolytic viruses, and toll-like receptors. Although clinical benefits have been shown in specific case reports and trials, various challenges remain to be resolved to guarantee applicability in the general patient population. Standing on the shoulders of pioneers expedites the pace of advances in therapeutic cancer vaccines, making them the rising star in the field of immunotherapy.Keywords
Funding Information
- Tri-Service General Hospital (TSGH-E-112226)
This publication has 95 references indexed in Scilit:
- Efficacy and Safety of Vismodegib in Advanced Basal-Cell CarcinomaNew England Journal of Medicine, 2012
- Merkel Cell Polyomavirus-Specific CD8+ and CD4+ T-cell Responses Identified in Merkel Cell Carcinomas and BloodClinical Cancer Research, 2011
- Roles of the immune system in skin cancerBritish Journal of Dermatology, 2011
- Merkel Cell Polyomavirus-Infected Merkel Cell Carcinoma Cells Require Expression of Viral T AntigensJournal of Virology, 2010
- Cancer-Testis Antigens and Immunosurveillance in Human Cutaneous Squamous Cell and Basal Cell CarcinomasClinical Cancer Research, 2010
- ILK expression in human basal cell carcinoma correlates with epithelial–mesenchymal transition markers and tumour invasionHistopathology, 2010
- Human squamous cell carcinomas evade the immune response by down-regulation of vascular E-selectin and recruitment of regulatory T cellsJournal of Experimental Medicine, 2008
- Reduction of immunosuppression for transplant-associated skin cancer: expert consensus surveyBritish Journal of Dermatology, 2006
- Cancer immunoediting: from immunosurveillance to tumor escapeNature Immunology, 2002
- HLA and β2‐microglobulin Expression in Basal and Squamous Cell Carcinomas of the SkinInternational Journal of Dermatology, 1985